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Summary The choice of systemic treatment for breast cancer depends on the tumour characteristics and stage of disease, and the patient's
age, general state of health, menopausal status and oestrogen receptor (ER) status. Traditionally, endocrine therapy has been reserved for
post-menopausal women, combination chemptherapy being more commonly used in premenopausal women. Chemotherapy remains the
only option for patients with ER-negative breast cancer. The 1992 EBCTCG overview showed that, overall, polychemotherapy as adjuvant
treatment for early breast cancer produced significant reductions in annual odds of recurrence and mortality, with a statistically significant
trend towards greater benefits in patients aged under 50 years. Several trials have shown combination chemotherapy with
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) to be more effective than single-agent chemotherapy in premenopausal women
with node-positive tumours. However, although CMF chemotherapy seems to be effective irrespective of menopausal status, this benefit
appears greatest in premenopausal women. The addition of anthracyclines to combination chemotherapy regimens has extended disease-
free and overall survival rates in both premenopausal and post-menopausal women, including those with ER-positive tumours. The use of
high-dose chemotherapy with stem cell support in early breast cancer is unjustified outside the clinical trial setting - current data indicate that
such treatment may result in increased morbidity without a reduction in disease recurrence. Tamoxifen is effective in ER-positive disease;
however, as yet few large comparative trials have compared endocrine treatment with chemotherapy in early breast cancer. Combination
chemoendocrine therapy may provide a greater benefit than tamoxifen alone in early breast cancer, but this requires further study.
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Over the past two decades, significant progress has been made in
the treatment of early breast cancer. These treatment approaches
have led to improvements in the survival of patients with this
disease, with a resultant downward trend in mortality (Olivotto et
al, 1994; Quinn and Allen, 1995; Game et al, 1997; Landis et al,
1998). The improvements have resulted from the broader applica-
tion of screening mammography (to increase early tumour detec-
tion) and the wider use of systemic adjuvant therapy, including
chemotherapy (Early Breast Cancer Trialists' Collaborative
Group, 1992; Swedish Breast Cancer Cooperative Group, 1996).
Ifdisease is detected early, the patient has the option ofconserva-
tive surgery, allowing preservation of the breast, and appropriate
use of systemic adjuvant therapies can reduce the risk of disease
recurrence. This overview gives a brief review of the role of
chemotherapy in early breast cancer, covering the selection of
appropriate chemotherapy, current established treatments and the
role ofcombined endocrine/chemotherapy.
SELECTION OF CHEMOTHERAPY
To optimize the outcome of therapy in early breast cancer, appro-
priate treatment must be selected for each patient. The choice of
systemic treatment depends on the tumour characteristics and the
stage of disease. The value of systemic therapy remains to be
defined in patients with small tumours (i.e. diameter < 1 cm) or
pure ductal carcinoma in situ (DCIS). Currently, no established
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endocrine therapy or chemotherapy is available for patients with
DCIS, although studies are currently in progress to evaluate the role
of endocrine therapy in this subgroup. In patients with small
favourable invasive cancers (invasive tumour < 1 cm), the
risk/benefit ratio forcurrently available adjuvant treatments may be
close to one. These patients have an excellent prognosis, and
approximately 90% ofthem are cured with local therapies.
Menopausal status and oestrogen receptor (ER) status play
important roles in therapy selection. Younger (premenopausal)
patients are more likely to have ER-negative tumours, and, for
women with ER-negative tumours, chemotherapy is the only
option. Traditionally, endocrine treatment has been reserved for
post-menopausal patients and chemotherapy is more commonly
used in premenopausal women. Patients with ER-positive
tumours, however, are suitable candidates for tamoxifen therapy,
regardless of their age (Fisher et al, 1996). Although
chemotherapy reduces the risk of disease recurrence and death
regardless ofER status, the choice ofagent depends on the general
health of the patient. Women with significant co-morbid condi-
tions may not be appropriate candidates for certain chemotherapy
regimens. For example, because of their association with cardiac
toxicity, anthracycline-based regimens are not suitable for patients
with symptomatic cardiac disease (Buzdar et al, 1985, 1997).
CHEMOTHERAPY FOR EARLY BREAST CANCER
The first trials of adjuvant chemotherapy in which drugs were
administered for prolonged periods involved single-agent treat-
ment with melphalan (Fisher et al, 1975). The results established
the value of adjuvant chemotherapy, although the drug was not
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very effective by today's standards. In the National Surgical
Adjuvant Breast and Bowel Project (NSABP) B-05 trial,
melphalan therapy was more effective than surgery alone with
respect to disease recurrence and 10-year survival rates in women
under 50 years old with node-positive tumours (Fisher et al, 1986).
In the search for improved efficacy, randomized trials were
conducted comparing single-agent melphalan treatment with
combination chemotherapy in premenopausal women. Most of
these trials showed that survival with combination chemotherapy
regimens, regardless of the combination, was superior to that
obtained with single agents (Early Breast Cancer Trialists'
Collaborative Group, 1992).
The landmark combination chemotherapy Milan trial compared
the outcome in a group of patients administered 12 cycles of
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with
that of another group who received no systemic treatment
(Bonadonna et al, 1976). This large-scale study demonstrated that
combination chemotherapy reduced the risk of disease recurrence
in premenopausal patients, and established CMF as a highly effec-
tive adjuvant treatment for early breast cancer. In premenopausal
women, CMF led to a highly significant difference in median
disease-free survival rate compared with control patients (differ-
ence of 109 months; P = 0.0005). There was little difference in the
survival of post-menopausal patients compared with controls
(difference of 5 months), thus highlighting a major difference
between premenopausal and post-menopausal women and their
response to treatment. A retrospective review of this study found
that ahigh proportion ofpatients over 50 years ofage had received
reduced doses ofchemotherapy, which may have accounted for the
apparent lack ofefficacy in this subgroup. It also showed that the
older patients who received at least 85% of the protocol planned
dose benefited in terms of disease-free survival compared with
those in the control group (Bonadonna and Valagussa, 1981).
Other possible reasons for the lack ofbenefit seen in women aged
over 50 years include different disease characteristics (more
hormone-dependent tumours and better differentiated tumours
which may be more inherently resistant to current therapies) and
competing causes ofdeath.
Since the Milan trial, CMF has become widely established as
the combination therapy of choice for early breast cancer.
Subsequent studies evaluating modifications of CMF have been
compared, with the addition of vincristine, prednisone or other
drugs showing no significant improvement.
Anthracycline-based combination chemotherapy
There have been a number of studies comparing anthracycline-
based and non-anthracycline-based combination chemotherapy
regimens, and a recent review suggests that the former may be
superior when used in appropriate doses and schedules (Fisher et
al, 1990). In the NSABP trial, four cycles of doxorubicin plus
cyclophosphamide (AC) or cyclophosphamide/doxorubicin/5-
fluorouracil (CAF) were shown to be equivalent to six cycles of
CMF, producing similar disease-free and overall survival rates in
women with node-positive breast cancer (Fisher et al, 1990).
A number of other studies have shown that doxorubicin-
containing regimens may be more effective than CMF in
premenopausal women with early breast cancer (Bonadonna et al,
1995; Levine et al, 1995; Coombes et al, 1996). In a prospective
European study, a regimen of sequential treatment with four
courses of doxorubicin followed by eight courses of CMF gave
significantly better relapse-free and overall survival rates than an
alternating regimen of two courses of CMF followed by one course
of doxorubicin for a total of 12 courses (Bonadonna et al, 1995).
In a randomized study comparing CMF with doxorubicin/
vincristine/cyclophosphamide/5-fluorouracil (AVCF), the latter
regimen significantly increased disease-free (P = 0.002) and
overall (P = 0.0025) survival rates in premenopausal women, with
a median follow-up time of 16 years (Figure 1) (Misset et al, 1996).
The use of anthracycline-based chemotherapy may also be
beneficial in post-menopausal women. For example, a Cancer
and Leukaemia Group B (CALGB) study compared CMF/
vincristine/prednisone (CMFVP) with CMFVP plus an escalating
dose of the VATH regimen (vinblastine/doxorubicin/thiotepa/
halotestin) (Perloff et al, 1996) in post-menopausal women with
stage II breast cancer. With a mean follow-up of 11.5 years, VATH
treatment produced significant improvements in disease-free
survival (P = 0.004) and overall survival (P = 0.043; median > 14
years versus 10 years) rates (Figure 2). These improvements were
significant in both premenopausal and post-menopausal women,
and in those with ER-positive tumours.
Since 1974, all patients treated for breast cancer at the MD
Anderson Cancer Center have received 5-fluorouracil/doxoru-
bicin/cyclophosphamide (FAC) chemotherapy with minor modifi-
cations. The disease-free survival rate at 10 years was 86% among
patients with negative nodes, compared with 68% in those with
1-3 positive nodes, 53% in those with 4-10 positive nodes and
33% in those with more than ten positive nodes (Figure 3). A total
of 309 patients with stage III breast cancer have also been treated,
and approximately 40% of them were free of disease at 10 years,
following a standard regimen of six cycles of FAC. Few disease
recurrences have been observed beyond 5-7 years of follow-up in
both groups ofpatients (Buzdar et al, 1997).
The most recent Early Breast Cancer Trialists' Collaborative
Group (EBCTCG) overview of the use of chemotherapy in the
treatment of early breast cancer was published in 1992 (Early
Breast Cancer Trialists' Collaborative Group, 1992). The 1992
overview showed that overall, polychemotherapy produced highly
significant reductions in annual odds of recurrence (28% standard
deviation [s.d.] 3) and mortality (16% s.d. 3) (2P < 0.00001)
compared with controls. Although there was a statistically signifi-
cant trend towards greater benefits in patients under 50 years of
age compared with those over 50 years of age (recurrence 28%
versus 17%; mortality 17% versus 9%, respectively), the effect of
polychemotherapy is still statistically significant in older women
compared with controls. It appears that the difference in response
between older and younger women is a 'quantitative' difference in
the size of response, not a 'qualitative' difference between
response and no response. These data serve to confirm the impor-
tant role ofchemotherapy in the early breast cancer setting.
Dose intensification with stem cell support
Recent research has focused on the possibility ofdose intensifica-
tion and high-dose chemotherapy with stem cell support. Dose
intensification beyond the conventional standard protocol doses
has not produced further reductions in the risk of disease recur-
rence, but has been associated with an increase in morbidity
(Buzdar et al, 1992; Wood et al, 1994; Wolmark et al, 1997). The
role of more intensive chemotherapy with peripheral stem cell or
bone marrow support is an area of active research, and, so far, no
results are available from randomized clinical trials. Such studies
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Figure 1 (A) Survival and (B) disease-free survival for premenopausal
patients according to chemotherapy received. Numbers in parentheses are
the numbers of patients at risk. AVCF, doxorubicin/vincristine/cyclophos-
phamide/5-fluorouracil; CMF, cyclophosphamide/methotrexate/5-fluorouracil.
Redrawn with permission from Misset et al (1996)
are being carried out in patients with advanced breast cancer and in
women with high-risk primary breast cancer with ten or more posi-
tive nodes after surgery or four or more positive nodes after neoad-
juvant chemotherapy (Bearman et al, 1996). The preliminary
results of at least two of these studies (Eastern Cooperative
Oncology Group [ECOG] and CALGB) are expected in late 1998.
One ofthe major concerns regarding the use ofanthracyclines in
early breast cancer has been the potential risk of cardiac dysfunc-
tion (Buzdar et al, 1985). In earlier studies, when doxorubicin was
given as a bolus, the risk of cardiac dysfunction was about 1%.
Cardiac events occurred soon after the last dose of doxorubicin
was administered, and, on updated analyses of these studies, no
delayed heart dysfunction was observed. Since 1982, when the
administration schedule of doxorubicin was changed to a slow
infusion, the risk ofcardiac dysfunction has been further reduced.
Only two patients in the study in whom doxorubicin was adminis-
tered as continuous infusion had cardiac dysfunction. Both had
symptomatic cardiac disease before the initiation of therapy, and
they were treated using these protocols because they had a high
risk ofdisease recurrence (Buzdar et al, 1992, 1997, 1998).
Current status of chemotherapy for early breast cancer
Based on current data, CMF and anthracycline-based regimens
remain the major chemotherapeutic options in the treatment of
early breast cancer and can significantly reduce the risk of recur-
rence and mortality. Of the two treatments, anthracycline-based
combinations probably provide the greatest reduction in disease
recurrence and death. High-dose chemotherapy with stem cell
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Figure 2 Probability of (A) disease-free survival and (B) overall survival by
treatment regimen. (-) Continued cyclophosphamide/methotrexate/5-
fluorouracil/vincristine/prednisone (CMFVP) vs (...) crossover to
vinblastine/doxorubicin/thiotepa/halotestin (VATH). Redrawn with permission
from Perloff et al (1996)
support should only be used in the context ofclinical trials because
no convincing data show that these treatments are associated with
superiordisease-free or overall survival rates. Chemotherapy is the
only option for patients with ER-negative tumours. Its effects are
most pronounced in premenopausal patients, although the risk of
disease recurrence is also reduced in post-menopausal women
especially those who are able to tolerate the full dose.
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Figure 3 Estimated survival for stage 11 breast cancer patients receiving adjuvant 5-fluorouracil/doxorubicin/cyclophosphamide (FAC) chemotherapy by nodal
status. Data from A Buzdar, MD Anderson Cancer Center, USA
THE ROLE OF CHEMOTHERAPY VERSUS
ENDOCRINE THERAPY IN PREMENOPAUSAL
WOMEN
One issue requiring clarification concerns the relative benefits of
chemotherapy and endocrine therapy in women under 50 years of
age. The 1992 EBCTCG overview showed that although there was a
significant 12% reduction in the riskofdisease recurrence in patients
aged under 50 years given tamoxifen monotherapy this was not
translated into a significant drop in mortality, which fell by only 6%
(Early Breast Cancer Trialists' Collaborative Group, 1992). This
contrasts with the findings in women aged over 50 years, in whom
adjuvant tamoxifen significantly reduced the risk of recurrence by
29% and of mortality by 20% (Early Breast Cancer Trialists'
Collaborative Group, 1992). Therefore, while cytotoxic chemo-
therapy offers the greatest benefit to premenopausal women,
endocrine treatment is mosteffective in women over 50 years of age.
An important question, therefore, is whether patients who are
ER-positive gain more benefit from endocrine treatment than from
chemotherapy, irrespective of their age. A possible answer to this
has been provided by the results of the NSABP B-14 study, which
enrolled patients with node-negative, ER-positive early breast
cancer (Fisher et al, 1996). At the 10-year follow-up, significant
benefits were observed in the rates of disease-free survival (67%
versus 57%; P < 0.0001), distant disease-free survival (76% versus
67%; P < 0.0001) and survival (80% versus 76%; P = 0.02) in
patients who received tamoxifen compared with those administered
placebo. This benefit was seen both in women under 50 years old
and in those aged 50 years and over. In a follow-up to this study
(NSABP B-20), treatment with tamoxifen alone was compared
with tamoxifen after methotrexate/5-fluorouracil and tamoxifen
after CMF in node-negative, ER-positive breast cancer (Fisher et
al, 1997). Tamoxifen after CMF therapy resulted in a significant
benefit in disease-free survival over tamoxifen alone (P < 0.01),
with a trend to improved overall survival. Similar results were
obtained in women regardless ofthe age ofthe patients.
Tamoxifen, therefore, is effective in patients with ER-positive
tumours irrespective of their age; however, no convincing data
currently exist regarding the comparison of endocrine therapy with
chemotherapy alone in the treatment of early breast cancer. It is
possible that a combination ofchemotherapy plus tamoxifen may be
more effective than tamoxifen alone in ER-positive disease, but this
needs to be confirmed in additional studies. The risks associated
with combined chemoendocrine therapy must also be considered,
and in some patients the risk ofthromboembolic complications may
outweigh any possible benefit (Pritchard et al, 1996).
The available treatment modalities have undoubtedly had a
significant impact on the natural history ofbreast cancer, but there
is still considerable scope for improvement. Several new agents
(both cytotoxic and endocrine) are being evaluated, including
taxanes, vinorelbine, aromatase inhibitors and goserelin. These
have shown efficacy in previously treated advanced disease, and
may be appropriate in the future for early breast cancer. The results
of trials currently in progress will provide important information
on the role ofthese agents and how they may best be used as alter-
natives to, or in combination with, current chemotherapeutic
agents in the treatment ofearly breast cancer.
CURRENT RECOMMENDATIONS FOR EARLY
BREAST CANCER TREATMENT
There are a number of current recommendations for the treatment
of early breast cancer (Table 1). For women with ER-negative
disease, combination chemotherapy should be given as standard
care, regardless of the age of the patient. Combined chemo-
endocrine therapy has a role in women with ER-positive disease,
Table 1 Current recommendation for the treatment of early breast cancer
* Patients of any age with ER-negative disease
Combination chemotherapy (anthracycline containing combination better)
* Patients with ER-positive disease
Chemoendocrine therapy, but need to consider possible increased
morbidity (thromboembolism)
* Patients of any age with ER-positive stage disease (good prognosis)
Endocrine therapy (tamoxifen)
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